menu
    • menu

    Company profile for CuraSen Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. More than 400 clinical trials were conduct...
    CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. More than 400 clinical trials were conducted with experimental therapies for Alzheimer’s disease between 2002 and 2012, and nearly all have failed; and that trend has continued more recently.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CuraSen TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    930 Brittan Avenue #306 San Carlos CA 94070
    Telephone
    Telephone
    650-475-2842
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.curasen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Curasen Reveals Positive Phase 1 Data On Curaax At AAS 2025
    Curasen Reveals Positive Phase 1 Data On Curaax At AAS 2025

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110216990/en/CuraSen-Therapeutics-Presents-Positive-Phase-1-Safety-Pharmacokinetics-and-Pharmacodynamics-Data-with-CuraAX-CST-3056-at-the-2025-American-Autonomic-Society-AAS-International-Symposium

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    Curasen Initiates Phase 2a Study For Curaax In nOH Study
    Curasen Initiates Phase 2a Study For Curaax In nOH Study

    23 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251023482535/en/CuraSen-Therapeutics-Doses-First-Patient-with-CuraAX-CST-3056-in-Phase-2a-Neurogenic-Orthostatic-Hypotension-nOH-Study

    BUSINESSWIRE
    23 Oct 2025
    Share Share
    CuraSen Doses First Subject With CuraAX (CST-3056) In Ph 1 Trial
    CuraSen Doses First Subject With CuraAX (CST-3056) In Ph 1 Trial

    20 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250220404883/en

    BUSINESSWIRE
    20 Feb 2025
    Share Share
    CuraSen Therapeutics Appoints Kathleen Sereda Glaub CEO
    CuraSen Therapeutics Appoints Kathleen Sereda Glaub CEO

    15 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241015764207/en

    BUSINESSWIRE
    15 Oct 2024
    Share Share
    CuraSen Announces Presentation of Positive Phase 2a Data with CST-2032/CST-107
    CuraSen Announces Presentation of Positive Phase 2a Data with CST-2032/CST-107

    07 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240307105858/en

    BUSINESSWIRE
    07 Mar 2024
    Share Share
    CuraSen Announces Investment from Alzheimer’s Drug Discovery Foundation
    CuraSen Announces Investment from Alzheimer’s Drug Discovery Foundation

    09 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231009260194/en

    BUSINESSWIRE
    09 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search